A Study to Evaluate Changes in Smokers Using Oral Tobacco-derived Nicotine Products.

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

231 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-05-30

Study Completion Date

2018-10-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate changes in exposure to selected harmful and potentially harmful constituents (HPHC) by measuring biomarkers in adult smokers who partially or completely switch from smoking cigarettes to oral tobacco-derived nicotine (OTDN) products compared to those who continue exclusive smoking cigarettes or stop using all tobacco products.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Evaluate Changes in Smokers Using An Oral Tobacco-Derived Nicotine Product

NCT04079933

Tobacco Use

COMPLETED NA

Study to Evaluate Changes in Smokers Using on!® Nicotine Pouches

NCT05664672

Tobacco Use

COMPLETED NA

Nicotine Pharmacokinetics and Subjective Effects of Oral Nicotine Products Relative to Smokeless Tobacco in Adult Users

NCT06691386

Tobacco Use

COMPLETED NA

Comparative Pharmacokinetic Study of New Oral Nicotine Replacement Therapy Products.

NCT01227720

Tobacco Dependence

COMPLETED NA

Pharmacokinetic and Subjective Effects of Heated Tobacco Products

NCT06356610

Tobacco Use

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is an open label, randomized, 6 parallel-group clinical study evaluating changes in exposure to selected HPHCs, subjective effects, and product use behavior in adult smokers relative to continued smoking who are randomly assigned to continue smoking, partially or completely switch to oral tobacco-derived nicotine products, or stop using any tobacco products for 7 days.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tobacco Use

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

GROUP 1: Continue Smoking

Subjects will be asked to continue smoking their own brand (OB) cigarettes ad libitum for 7 days.

Group Type NO_INTERVENTION

No interventions assigned to this group

GROUP 2: OTDN product 1

Subjects will reduce their normal daily cigarette consumption by at least 50% of their baseline cigarettes per day (CPD) and use at least 3 oral tobacco-derived nicotine (OTDN) product units per day for 7 days.

Group Type EXPERIMENTAL

OTDN product 1

Intervention Type OTHER

Oral tobacco-derived nicotine product

GROUP 3: OTDN product 2

Subjects will reduce their normal daily cigarette consumption by at least 50% of their baseline CPD and use at least 3 oral tobacco-derived nicotine (OTDN) product units per day for 7 days.

Group Type EXPERIMENTAL

OTDN product 2

Intervention Type OTHER

Oral tobacco-derived nicotine product

GROUP 4: OTDN product 1

Subjects will completely switch to exclusive use of an oral tobacco-derived nicotine (OTDN) product, using at least 3 OTDN product units per day for 7 days.

Group Type EXPERIMENTAL

OTDN product 1

Intervention Type OTHER

Oral tobacco-derived nicotine product

GROUP 5: OTDN product 2

Subjects will completely switch to exclusive use of an oral tobacco-derived nicotine (OTDN) product, using at least 3 OTDN product units per day for 7 days.

Group Type EXPERIMENTAL

OTDN product 2

Intervention Type OTHER

Oral tobacco-derived nicotine product

GROUP 6: Tobacco Cessation

Subjects will completely stop all tobacco product usage for 7 days.

Group Type EXPERIMENTAL

Tobacco Cessation

Intervention Type OTHER

Tobacco Cessation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

OTDN product 1

Oral tobacco-derived nicotine product

Intervention Type OTHER

OTDN product 2

Oral tobacco-derived nicotine product

Intervention Type OTHER

Tobacco Cessation

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Voluntary consent to participate in this study documented on the signed informed consent form (ICF).
2. Healthy adult males and females 21 to 65 years of age, inclusive, at Screening
3. Smoking history of an average of at least 10 but no more than 30 factory manufactured combustible cigarettes daily for at least 1 year prior to Screening. Brief periods (i.e., up to 7 consecutive days) of non-smoking during the 3 months prior to Screening (e.g., due to illness or participation in a study where smoking was prohibited) will be permitted.
4. Positive urine cotinine (≥ 500 ng/mL) at Screening.
5. Willing to comply with the requirements of the study.
6. Willing to use all test products after product trial at Check in.
7. Willing and able to abstain from cigarettes from Day 1 through the End of the study.

Exclusion Criteria

1. Use of any type of tobacco or nicotine containing products other than manufactured cigarettes (e.g., e vapor products, roll-your-own cigarettes, bidis, snuff, nicotine inhaler, pipe, cigar, chewing tobacco, nicotine patch, nicotine spray, nicotine lozenge, or nicotine gum) in the 7 days prior to Check in
2. Self-reported puffers (i.e., adult smokers who draw smoke from the cigarette into the mouth and throat but do not inhale).
3. Planning to quit smoking in the next 30 days (from Screening visit).
4. History or presence of clinically significant gastrointestinal, renal, hepatic, neurologic, hematologic, endocrine, oncologic, urologic, existing respiratory diseases, immunologic, psychiatric, lymphatic, or cardiovascular disease, or any other condition that, in the opinion of the Investigator, would jeopardize the safety of the subject or impact the validity of the study results.
5. Clinically significant abnormal findings on the vital signs, physical examination, medical history, ECG, or clinical laboratory results, in the opinion of the Investigator.

Minimum Eligible Age

21 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes